Today's top medical abstracts
Oncology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?

Home
General Oncology
For Practicing
Oncologists
Conferences
Jobs
Newsletters
My Library
Topics in
Oncology
        Alternative Therapies
        Anemia/Polycythemia
        BMT/SCT
        Basic Science/Genetics
        Bone/Cartilage
        Breast
        Carcinogenesis
        Coagulation/Bleeding Dz
        Colorectal Cancer/Polyps
        Dermatologic Oncology
        Diagnostics/Radiology
        Economics of Medicine
        Endocrine Oncology
        GI Oncology
        Gynecologic Oncology
        Head and Neck
        Hepatobiliary/Pancreas
        Leukemia/Lymphoma
        Lung/Thoracic Oncology
        Myeloproliferative Dz
        Neurologic Oncology
        Pain/Palliative Care
        Pediatric Heme/Oncology
        Pharmacology/Therapy
        Popular Press
        Renal/Urologic
        Side Effects
        Soft Tissue/Sarcoma
        Transfusion Medicine
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
For Practicing Oncologists
Technology Advances: CISH technology Facilitates Assay of HER2 Expression
Dorothy J. Schirf, MD, MDLinx Oncology
Today's Oncology News: VEGFb Designated Orphan Drug Status By FDA
D Scott Cunningham MD, PhD, MDLinx Oncology
  See all
astrocytomas Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website
Outcome analysis of childhood low-grade astrocytomas
Pediatric Blood & Cancer, 04/17/08
Print     Email This Article     Save in My Library   Free Abstract
Fisher PG et al. – Long-term overall survival (OS) is excellent for pts with low-grade astrocytomas (LGAs), particularly pilocytic astrocytomas (PAs); although tumor location and resection extent affect outcome, pathologic diagnosis significantly influences long-term survival; immediate postoperative irradiation offers no advantage in delaying first progression in children with residual PA

Methods

  • Study of long-term natural history of LGAs in children in terms of pathology and treatment effect on survival
  • Review of a consecutive cohort of pts from 1965-1996 with surgically confirmed LGA
  • All pathology specimens reviewed and masked to original diagnosis, pt data, and neuroimaging

Results
  • Of 278 children, 160 were male; mean age 9.1 yr; tumor location: 77 cerebrum, 62 cerebellum, 51 hypothalamic, 30 thalamus, 9 ventricle, 40 brainstem, 9 spine
  • Of 246 specimens, diagnoses were: 135 PA, 27 diffuse astrocytoma (DA), 75 unclassifiable well-differentiated astrocytoma (NOS), and 9 subependymal giant cell astrocytoma
  • OS for all LGA 5 and 10 yr after initial surgery: 87% and 83%; progression-free survival (PFS): 55% and 42%, respectively
  • Original pathology diagnoses did not predict PFS; reviewed diagnoses were significantly associated with PFS
  • Reviewed diagnoses were highly associated with OS; 5-year OS for PA was 96%, DA 48%, NOS 86%; differences remained significant when stratified by location or resection extent
  • In pts with residual tumor post-surgery, 5-year PFS with observation alone did not differ from that with immediate irradiation

Sponsor
Read a Different Specialty
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology
Profession Index
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2008 MDLinx, Inc.